MTRC released a White Paper with a summary of clinical evidence requirements for the LPPR process for implants and invasive devices in France

In France, reimbursements for hospital procedures are made solely via a DRG system, which is called “Groupe Homogène de Maladies” (GHM). All hospitalizations, as well as day case procedures and ambulatory treatments, are reimbursed via DRG.

However, there is a possibility of add-on reimbursement (on top of the DRG tariff) via LPPR List. Add-on reimbursement is possible for selected implantable (Title III) or invasive non-implantable (Title V) devices. 

Clinical assessment is performed by the National Committee for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS), and price negotiation is performed by the Economic Committee on Healthcare Products (CEPS).

MTRC released a White Paper with a summary of clinical evidence requirements for the LPPR List process for implants and invasive devices in France

In this White Paper, we identified evidence requirements for national add-on reimbursement via the LPPR List process based on an analysis of five recent HAS reports with positive recommendations. Cases included technologies with different levels of added clinical value (II, III, IV, and V). A review of five cases is followed by recommendations in relation to evidence generation for medical technologies in France, and factors influencing the decision-making of HAS. The analysis was performed in February 2024.

Read more and request a White Paper here.